Navigation Links
Cephalon Reported Financial Results for the Second Quarter of 2011
Date:8/2/2011

ge in fair value of investments adjustments

(264,208)

(9)

-Other (income) expense adjustment

16,989

(10)

11,567

(10)Income tax adjustment

39,359

(11)

(38,690)

(11)*Noncontrolling Interest adjustments:Other revenues

-(31)Research and development

1,4176,094Selling, general and administrative1,0633,222Other income (expense)

-166Interest income

-(7)Interest expense

723154Income taxes

-(3,848)Less amount attributable to noncontrolling interest

(3,203)(5,750)(28,267)109,610ADJUSTED NET INCOME ATTRIBUTABLE TO CEPHALON, INC.

$ 300,996$ 309,239BASIC ADJUSTED INCOME PER COMMON SHARE

$
3.95$
4.12DILUTED ADJUSTED INCOME PER COMMON SHARE

$
3.63$
3.81WEIGHTED AVERAGE NUMBER OF COMMONSHARES OUTSTANDING

76,21375,092WEIGHTED AVERAGE NUMBER OF COMMONSHARES OUTSTANDING-ASSUMING DILUTION

82,87181,223* Amounts recorded by our Variable Interest Entities that have been excluded from net income attributable to Cephalon, Inc.Notes to Reconciliation of GAAP Net Income to Adjusted Net Income(1) To exclude the on-going amortization of acquired intangible assets ($56.0M in 2011; $58.0M in 2010), the reversal of a royalty accrual related to AMRIX sales milestones that are no longer expected to be payable ($27.8M in 2011), accelerated depreciation related to restructuring ($10.7M in 2010), amortization of inventory revaluation related to Mepha ($5.0M in 2010) and the write-off of modafinil purchase commitments in excess of estimated requirements ($9.4M in 2010).(2) To exclude accelerated depreciation related to restructuring.(3) In 2011, to exclude charges related to the unsolicited proposal we received from Valeant Pharmaceuticals International and the Agreement and Plan of Merger with Teva Pharmaceutical Industries Ltd. ($20.9M), and charges associated with recent acquisitions.  In 2010, to exclude charges related to t
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Cephalon Quarterly Conference Call Invitation
2. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices
3. $425 Million Cephalon Civil Settlement and Criminal Fine; In Americas Largest
4. Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications
5. Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules
6. Cephalon Reports Another Strong Quarter
7. Cephalon, Inc. to Webcast Analyst Day
8. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
9. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
10. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
11. Cephalons New Product Launches Pace Record 2008 Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... 2015 , ... R-Biopharm is proud to announce the RIDASCREEN® ... foods, has been accepted by AOAC International as Official First Action method. The ... Products by R5 Competitive ELISA,” based on a specific monoclonal antibody to potentially ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Vieillard as Sales & Marketing Director. , With more than 25 years ... responsible for reinforcing Tronics’ business development activities worldwide. He brings to the company ...
(Date:7/30/2015)... Kan. , July 30, 2015   ... a pet therapeutics company focused on the licensing, ... companion animals, today announced that its strategic partner ... a dose confirmation study of AT-016, an adipose-derived ... for the treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... LOUIS, July 30, 2015 HIGHLIGHTS:Q2 ... in 2014) , Reported sales were $697 million ... 2014.  Sales grew organically by 8%, and changes in ... acquisitions increased sales by 1%. , By business ... in Applied and 11% in SAFC Commercial. , ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Tronics appoints Francois Vieillard as Sales and Marketing Director 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... 21, 2012 International scientific and government experts ... potential use of Oxitec,s genetically modified Aedes aegypti ... The independent forum was co-organised by the Smithsonian ... Studies and the University of Panama. This brought together national ...
... ROCKVILLE, Md., May 21, 2012  Neuralstem, Inc. (NYSE ... President, will present at the World Stem Cells ... ) on Tuesday, May 22nd at 12:30 PM. ... Disorders," will review Neuralstem,s cellular therapy trial in ...
... 18, 2012 Champions Oncology Inc. (OTC: CSBR) announced ... Amendment (CLIA) certification from the Maryland Department of Health ... for the company to conduct medical laboratory tests. ... "Obtaining CLIA approval is a significant milestone for our ...
Cached Biology Technology:Expert Meeting Discusses Testing of Oxitec Transgenic Mosquitoes in Panama 2Expert Meeting Discusses Testing of Oxitec Transgenic Mosquitoes in Panama 3Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London 2Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities 2Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities 3
(Date:7/31/2015)... China , 31 de julio de 2015 ... www.icg-10.org ) se celebrará por medio de BGI del 22 al ... . Este año, la conferencia celebra ... ICG se ha convertido en una de las reuniones anuales ... ser una de las reuniones más dinámicas, entusiastas y mejores ...
(Date:7/31/2015)... 2015 The 10 th International Conference on ... October 22-25, 2015, in Shenzhen , ... celebrating its 10 th anniversary this year. Since its inauguration ... influential annual meetings in the ,omics, fields, and is one ... ICG-10 focuses on recent breakthroughs and advances in ...
(Date:7/27/2015)... July 27, 2015   Zynx Health ™, ... clinical improvement solutions, today announced that its ... available on Android smartphones and tablets. With this ... organizations can use ZynxCarebook to securely exchange messages ... streamline care transitions to other care settings, and ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... and controversial technical barrier in stem cell biology, scientists ... Wisconsin-Madison have crafted a recipe that allows researchers to ... mouse-derived "feeder" cells, long thought to be a source ... The new findings, appear today (Feb. 17) in the ...
... other marine creatures, Aplysia, a common sea slug, enlists ... which such chemical attacks actually work against their intended ... has now shown that such chemical defenses can involve ... as components of chemical defense. , When attacked by ...
... by interfering with the biochemical signals one ovarian cell ... led by scientists at the USC/Norris Comprehensive Cancer Center ... of Southern California. , Their work is being published ... Biology. , "Before, we thought this gene was a ...
Cached Biology News:Scientists rid stem cell culture of key animal cells 2Scientists rid stem cell culture of key animal cells 3In the sea slug's defense against lobsters, confusion is key 2BRCA1 causes ovarian cancer through indirect, biochemical route 2BRCA1 causes ovarian cancer through indirect, biochemical route 3
Rat CXCL7/Thymus Chemokine-1 DuoSet Economy Pack, 45 Plate...
Recombinant Rat Fas Ligand/TNFSF6...
FGF Receptor 1 Antibody...
Rabbit polyclonal to Kallikrein 1 ( Abpromise for all tested applications). Antigen: Full length native kallikrein from tissue (Human) Entrez Gene ID: 3816 Swiss Protein ID: P06870...
Biology Products: